Market Share of Pharmaceutical CMO Industry
Although the market studied is highly fragmented, major vendors account for most of the market share. The presence of many players in the market studied impacts the pricing of services, making it a direct competing factor, especially for small-scale vendors. The vendors in the market studied are expected to focus on providing one-stop-shop services, providing them with a competitive advantage. These practices would be possible for the CMOs with access to large capital. This factor increases the competition and creates a new players' entry barrier. Some of the major players in the market are Patheon Inc. (Thermo Fisher Scientific Inc.), Lonza Group, Catalant Inc., Pfizer CentreOne (Pfizer Inc.), Boehringer Ingelheim Group, etc.
In June 2023, OneBioSuite, an integrated development, production, and supply solution from Catalent, was developed to include various biologic modalities, including mRNA, cell and gene therapies, antibody and recombinant proteins, and recombinant proteins. The debut of the extended service will take place in conjunction with Catalent's participation in the BIO International Convention (booth 785) in Boston from June 5-8, 2023.
In December 2022, RedHillBiopharma's medication Talicia used to treat H. pylori infection, would continue to manufacture commercially by Recipharmthrough 2026. RedHilland Recipharmhave worked closely since 2015 to develop and manufacture Talicia (delayed-release capsules, omeprazole magnesium, amoxicillin, and rifabutin, 10 mg/250 mg/12.5 mg).
Pharmaceutical CMO Market Leaders
Catalent Inc.
Recipharm AB
Jubilant Biosys Ltd.(Jubilant Pharmova Ltd)
Patheon Inc. (Thermo Fisher Scientific Inc.)
Boehringer Ingelheim Group
*Disclaimer: Major Players sorted in no particular order
_Market.webp)
